Inject Solesta: For well-studied safety and tolerability through 36 months¹

1. 96% of adverse events were mild or moderate over 18 months¹

   • 96% of the events required no intervention or required medical or simple noninvasive interventions¹

2. The most common types of adverse events were proctalgia, minor anal or rectal bleeding (hemorrhage), pyrexia, abdominal complaints (diarrhea and constipation), and injection-site pain¹

   • All instances of bleeding were listed as hemorrhages, regardless of intensity, in accordance with international standards²

   • Most treatment-related adverse events were experienced soon after injection with Solesta; the highest incidence occurred during the 48-hour interval following first injection¹

3. Only 3 adverse events assessed as related to Solesta, or 1.3% of the treatment-related adverse events, were deemed serious¹

Solesta has minimal post-procedure impact on patients¹

• Patients may resume limited physical activity immediately

• Patients are able to resume a normal lifestyle and engage in all physical activities after 1 week (e.g. jogging, bicycling, horseback riding, sexual intercourse, etc.)

• Solesta is unlikely to impede future procedures